MedTrace Logo

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

NCT04830501 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-11-21

No results posted yet for this study

Summary

This is a phase I study of the safety, tolerability, pharmacokinetics profile, and preliminary efficacy of TT-00434 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

TT-00434

Once daily \[QD\], 28 days/cycle.

Sponsors & Collaborators

  • TransThera Sciences (Nanjing), Inc.

    lead INDUSTRY

Principal Investigators

  • Huey En Tzeng · Taipei Medical University Hospital

  • Chia Jui Yen · National Cheng-Kung University Hospital

  • Ching Liang Ho · Tri-Service General Hospital

  • Ming Che Liu · Taipei Medical University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2023-10-18
Completion
2023-10-18

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830501 on ClinicalTrials.gov